Chardan lowered the firm’s price target on Krystal Biotech (KRYS) to $216 from $219 and keeps a Buy rating on the shares after the company announced it will be prioritizing the development of inhaled KB707 for the treatment of non-small cell lung cancer and de-prioritizing the development of KB707 in the intratumoral setting. In conjunction with the prioritization of inhaled KB707, Krystal has paused enrollment in the intratumoral OPAL-1 trial, notes the analyst, who expects additional color on the go forward plan and an update on FDA interactions with Q3 earnings due in November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech says prioritizing inhaled KB707
- Krystal Biotech says prioritizing inhaled KB707, pauses enrollment in OPAL-1
- Krystal Biotech pauses enrollment in OPAL-1 Phase 1/2 trial
- Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges
- Krystal Biotech: Strong Financial Performance and Strategic Growth Initiatives Support Buy Rating